Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00YZD
|
|||
| Former ID |
DNCL002987
|
|||
| Drug Name |
Dolutegravir
|
|||
| Synonyms |
1051375-16-6; GSK1349572; Tivicay; S/GSK1349572; Dolutegravir (GSK1349572); S-349572; GSK-1349572; GSK 1349572; UNII-DKO1W9H7M1; (4r,12as)-N-(2,4-Difluorobenzyl)-7-Hydroxy-4-Methyl-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-2h-Pyrido[1',2':4,5]pyrazino[2,1-B][1,3]oxazine-9-Carboxamide; CHEBI:76010; DKO1W9H7M1; Tivicay (TN); (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; Dolutegravir Sodium (
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Approved | [1], [2] | |
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H19F2N3O5
|
|||
| Canonical SMILES |
CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
|
|||
| InChI |
1S/C20H19F2N3O5/c1-10-4-5-30-15-9-24-8-13(17(26)18(27)16(24)20(29)25(10)15)19(28)23-7-11-2-3-12(21)6-14(11)22/h2-3,6,8,10,15,27H,4-5,7,9H2,1H3,(H,23,28)/t10-,15+/m1/s1
|
|||
| InChIKey |
RHWKPHLQXYSBKR-BMIGLBTASA-N
|
|||
| CAS Number |
CAS 1051375-16-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
96100998, 123055423, 124361075, 124361082, 124361088, 135268073, 135273443, 135626786, 136340316, 136349541, 136367672, 136920429, 144115916, 152258477, 160647312, 160693271, 162011364, 162038052, 162202774, 163677014, 164043525, 164193963, 164347381, 170484068, 170484069, 170484070, 170503405, 174007466, 174525979, 175427161, 178103937, 184812380, 189622844, 198935766, 198993556, 223382143, 223705174, 226460906, 242590891, 248390482, 250184664, 252110159, 252224388, 252451605
|
|||
| ChEBI ID |
CHEBI:76010
|
|||
| ADReCS Drug ID | BADD_D00704 | |||
| SuperDrug ATC ID |
J05AX12
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Integrase (HIV IN) | Target Info | Modulator | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7365). | |||
| REF 2 | Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. | |||
| REF 3 | Clinical pipeline report, company report or official report of Shionogi (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.